Litigation Details for Indivior Inc. v. Alvogen Pine Brook LLC (D. Del. 2015)

Indivior Inc. v. Alvogen Pine Brook LLC (D. Del. 2015)

Docket		Date Filed	2015-06-10
Court	District Court, D. Delaware	Date Terminated	2018-05-08
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	8,017,150; 8,475,832; 8,603,514
Link to Docket	External link to docket

Details for Indivior Inc. v. Alvogen Pine Brook LLC (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-10				External link to document
2015-06-10	1		of United States Patent Nos. 8,475,832 (“the ʼ832 patent”), 8,017,150 (“the ʼ150 patent”), 8,603,514 (…832 patent, the ’150 patent, and the ’514 patent (collectively, the “Orange Book- Listed Patents”) are… (“the ’514 patent”), 8,900,497 (“the ’497 patent”), and 8,906,277 (“the ’277 patent”) (collectively,…the ʼ150 patent, and Plaintiff RBP is an exclusive licensee of the ʼ150 patent. The ʼ150 patent, entitled…the ʼ514 patent, and Plaintiff RBP is an exclusive licensee of the ʼ514 patent. The ʼ514 patent, entitled	External link to document
2015-06-10	129	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,475,832 ;8,017,150 ;8,603,514 ;8,900,497…June 2015 8 May 2018 1:15-cv-00477 830 Patent None District Court, D. Delaware	External link to document
2015-06-10	4		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,475,832; 8,017,150; 8,603,514… 10 June 2015 1:15-cv-00477 830 Patent None District Court, D. Delaware	External link to document

Indivior Inc. v. Alvogen Pine Brook LLC, 1:15-cv-00477: Litigation Summary and Patent Analysis

Last updated: August 5, 2026

Indivior sued Alvogen in the District of Delaware after Alvogen filed an abbreviated new drug application seeking FDA approval for generic buprenorphine and naloxone sublingual film, the generic equivalent of Suboxone Film. The case involved Indivior’s formulation and manufacturing patents, including U.S. Patent Nos. 8,603,514 and 8,900,497. The public docket reflects a Hatch-Waxman patent dispute that concluded through settlement and stipulated dismissal rather than a final merits judgment against Alvogen. The settlement terms and any authorized launch date were not publicly disclosed in the case record.[1]

What was Indivior Inc. v. Alvogen Pine Brook about?

The case concerned Alvogen’s ANDA for a generic buprenorphine/naloxone film product. Indivior alleged that the proposed ANDA product would infringe patents listed in the FDA’s Orange Book for Suboxone Film.

Suboxone Film contains:

Component	Function
Buprenorphine	Partial opioid agonist used in medication-assisted treatment for opioid dependence
Naloxone	Opioid antagonist included to deter intravenous misuse
Dosage form	Sublingual transmucosal film
Regulatory pathway	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Reference product	Suboxone Sublingual Film

The litigation was a standard Paragraph IV case. Alvogen’s ANDA certification asserted that the relevant Indivior patents were invalid, unenforceable, or would not be infringed by the proposed generic product. Indivior responded by filing suit within the statutory period, triggering the Hatch-Waxman 30-month approval stay under 21 U.S.C. § 355(j)(5)(B)(iii).[2]

Which patents did Indivior assert against Alvogen?

The principal patents associated with the Alvogen Suboxone Film litigation were U.S. Patent Nos. 8,603,514 and 8,900,497.

Patent	General subject matter	Relevance to Suboxone Film
U.S. 8,603,514	Drug-containing oral film compositions and related formulation characteristics	Covered aspects of the film dosage form and composition
U.S. 8,900,497	Oral film formulations and properties relevant to drug delivery	Covered additional formulation limitations used in Suboxone Film
Later Suboxone patents	Additional formulation, dosage, and manufacturing claims	Became relevant to subsequent generic litigation and Orange Book strategy

The patents were directed at more than the active ingredients themselves. Buprenorphine and naloxone were known compounds. Indivior’s infringement theory depended on narrower intellectual-property claims involving film architecture, drug distribution, composition, dosage characteristics, and manufacturing controls.

The asserted rights therefore had a different risk profile from a conventional active-ingredient patent. A generic manufacturer could avoid a composition patent by using a different formulation, but it would need to assess whether the alternative still fell within the patented film structure or process limitations.

What was the procedural history of the case?

The case was filed in 2015 in the U.S. District Court for the District of Delaware under Civil Action No. 1:15-cv-00477. Indivior was the plaintiff, and Alvogen Pine Brook LLC was the principal defendant.

The material procedural sequence was:

Event	Significance
May 2015	Indivior filed the patent-infringement action after receiving Alvogen’s Paragraph IV notice
2015-2017	Claim construction, discovery, and preparation for merits proceedings
During the litigation	The parties negotiated a commercial resolution
Case termination	The action ended through a stipulated dismissal rather than a publicly reported final infringement or invalidity judgment

The public docket does not establish a published trial judgment deciding the validity or infringement of every asserted claim. This distinction matters. A stipulated dismissal does not provide the same precedent as a Federal Circuit opinion or a final district-court judgment after trial.

Did Alvogen challenge Indivior’s patents under Paragraph IV?

Yes. The case arose from Alvogen’s Paragraph IV certification in connection with its ANDA for generic buprenorphine/naloxone sublingual film.

A Paragraph IV certification alleges that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The filing gives the brand company an opportunity to sue before FDA approval. The litigation also delays FDA approval for up to 30 months, subject to statutory exceptions and court action.[2]

The commercial effect of Alvogen’s Paragraph IV filing depended on several factors:

1. Whether Alvogen was a first applicant for the relevant ANDA strength or formulation.
2. Whether Alvogen retained or forfeited any 180-day generic exclusivity.
3. Whether the settlement permitted an earlier launch than the asserted patent expiry dates.
4. Whether other generic applicants could obtain approval independently.
5. Whether later patent litigation altered the commercial launch timetable.

The Alvogen case did not produce a publicly reported appellate decision establishing that Alvogen’s proposed product infringed the asserted patents.

What was the outcome of the Indivior-Alvogen litigation?

The case ended without a publicly reported merits decision against Alvogen. The docket reflects a settlement-related resolution and stipulated dismissal.

The publicly available record does not disclose the full commercial terms. As a result, the following points cannot be treated as established by the docket alone:

• The exact agreed launch date.
• Whether Alvogen received a license to launch before patent expiry.
• Whether the agreement included an authorized-generic arrangement.
• Whether the parties exchanged consideration tied to market entry.
• Whether Alvogen agreed to restrictions on product development or launch.
• Whether the agreement addressed later-issued Indivior patents.

The absence of a merits judgment reduced immediate precedent risk for Indivior. It also preserved uncertainty concerning the enforceability and scope of the asserted patents against Alvogen’s specific ANDA formulation.

What was the Orange Book status of Suboxone Film?

Suboxone Film was protected by a portfolio of formulation and delivery patents rather than by a single compound patent. FDA Orange Book listings are central to assessing ANDA timing because listed patents determine the certifications that an applicant must make and can trigger a statutory approval stay.[3]

The relevant Orange Book categories included:

• Formulation patents.
• Dosage-form patents.
• Drug-delivery patents.
• Method-of-use patents.
• Patents covering specific strengths or administration characteristics.

Orange Book status must be analyzed patent by patent. The expiration of one patent does not necessarily eliminate all regulatory or litigation barriers if other listed patents remain in force.

The commercial importance of the patents also depended on whether a listed patent covered the approved product as marketed or only a narrower formulation feature. A patent with broad practical coverage can delay meaningful generic competition even when its claim language is technically narrow. A narrow patent may have limited value if a generic applicant can design around it.

When did Indivior’s Suboxone patents lose exclusivity?

The relevant exclusivity dates differed by patent and by any patent-term adjustment or extension. The principal patents in the litigation did not have identical expiration profiles.

The most important legal distinction is between:

Protection type	Effect
FDA regulatory exclusivity	Restricts FDA approval activity for a specified period
Patent protection	Allows the owner to block commercial activity within the patent claims
Orange Book listing	Connects a patent to the ANDA certification and litigation process
Settlement license	Can permit launch before patent expiry under agreed conditions

Suboxone Film’s commercial protection was also affected by pediatric exclusivity, patent-term calculations, later-issued patents, and settlements with other generic companies. The case-specific docket did not establish a single universal “Suboxone exclusivity date” applicable to every generic applicant.

What patent litigation affected generic Suboxone Film?

Indivior pursued multiple patent actions against generic applicants, including disputes involving Dr. Reddy’s Laboratories, Teva Pharmaceuticals, Mylan, and other companies. The litigation focused heavily on the ’514 and ’497 patents.

A significant later development involved U.S. Patent No. 8,603,514. In separate litigation, the Federal Circuit held that asserted claims of the ’514 patent lacked adequate written-description support for the full range of formulations claimed.[4] That ruling weakened Indivior’s ability to use the patent broadly against generic film products.

The appellate analysis focused on whether the patent specification supported the broad claimed range, rather than only the narrower examples disclosed in the patent. The decision was commercially important because it limited the enforceability of a core Suboxone Film patent against competing products.

The Alvogen case itself should not be treated as equivalent to the later Federal Circuit decisions. Alvogen obtained a settlement disposition. The later appellate cases involved different defendants, records, products, and litigation outcomes.

How strong was Indivior’s patent estate?

Indivior’s patent estate was commercially meaningful but uneven in legal strength.

Strengths

Indivior had several advantages:

• A branded product with substantial market share.
• A complex film dosage form that was harder to copy than a conventional tablet.
• Multiple formulation and manufacturing patents.
• Orange Book-listed patents capable of triggering ANDA litigation.
• Regulatory and technical barriers associated with demonstrating bioequivalence for a transmucosal film.
• The ability to pursue coordinated litigation against multiple generic applicants.

Weaknesses

The estate also had material vulnerabilities:

• The active ingredients were known and not protected by a new chemical entity patent.
• Formulation claims could be attacked for lack of written description, enablement, or obviousness.
• Generic manufacturers could attempt design-around formulations.
• Broad claim scope was vulnerable when the specification disclosed only limited examples.
• Later Federal Circuit decisions weakened the ’514 patent’s enforceability.
• Settlements reduced the number of disputes producing favorable precedent for Indivior.

The ’514 patent’s written-description failure illustrates the central risk in formulation patent litigation. A specification that supports one narrow embodiment may not support broad claims covering a wide range of polymer, drug-loading, or film-property combinations.

Did the litigation involve biosimilars?

No. This was not a biosimilar case.

Buprenorphine/naloxone sublingual film is a small-molecule drug product regulated through the ANDA pathway. The relevant competitors were generic-drug manufacturers, not biosimilar applicants under the Public Health Service Act.

The principal regulatory issues were:

• Paragraph IV certifications.
• ANDA approval.
• Bioequivalence.
• Product-specific labeling.
• Patent listing and the 30-month stay.
• Potential generic exclusivity.

Biosimilar concepts such as the patent dance under the Biologics Price Competition and Innovation Act were not applicable.

What manufacturing and formulation barriers did Alvogen face?

The technical barrier was not simply reproducing the buprenorphine and naloxone active ingredients. Alvogen had to develop a film that met FDA requirements for:

• Drug content uniformity.
• Film thickness and weight variation.
• Dissolution and drug release.
• Sublingual delivery.
• Mechanical integrity.
• Stability and impurity control.
• Naloxone and buprenorphine distribution.
• Packaging and moisture protection.
• Bioequivalence to the reference product.

Indivior’s patent strategy targeted these technical elements. Manufacturing patents can be valuable when the commercial product requires a narrow process window. Their strength depends on whether the generic’s process necessarily practices the claimed steps or whether the generic can use a different process while producing a comparable product.

For Alvogen, the primary risks were patent infringement, ANDA approval delay, development costs, launch uncertainty, and potential damages or injunctive relief. For Indivior, the principal risk was that an adverse written-description or obviousness ruling would invalidate a patent portfolio element before generic launch.

What was the commercial significance of the Alvogen settlement?

The settlement converted a binary litigation risk into a negotiated market-entry outcome. Indivior avoided the immediate risk of an adverse merits judgment. Alvogen avoided the cost and uncertainty of continued litigation and obtained a path toward commercialization subject to the negotiated terms.

The settlement’s business effects depended on whether it:

• Allowed an early generic launch.
• Preserved Indivior’s control over the launch date.
• Created an authorized-generic relationship.
• Covered only the products at issue or also later formulations.
• Limited Alvogen’s entry to particular strengths.
• Contained provisions affecting other generic applicants.

Settlement economics were especially important because generic Suboxone Film entry could materially reduce branded revenue. Once multiple generic manufacturers entered, price erosion and formulary substitution could accelerate rapidly.

Which companies challenged Suboxone Film patents?

Indivior faced patent challenges from several generic manufacturers. The principal names associated with the broader Suboxone Film patent disputes included:

• Alvogen.
• Dr. Reddy’s Laboratories.
• Teva Pharmaceuticals.
• Mylan.
• Other ANDA applicants involved in related proceedings.

The competitive landscape was shaped by the timing of each applicant’s Paragraph IV filing, the strength of its design-around formulation, settlement terms, and the availability of FDA approval.

A first-filer position could create substantial strategic value, but that value depended on preserving eligibility for 180-day exclusivity and avoiding forfeiture under the ANDA statute. A later filer could still enter if the first applicant forfeited exclusivity, if the brand settled on favorable terms, or if the later product avoided the remaining patent claims.

What generic launch risks existed after the case ended?

The Alvogen settlement did not eliminate generic-entry risk for Indivior. It changed the risk from an immediate adjudication to a portfolio and market-timing problem.

The principal risks were:

1. A settlement-authorized Alvogen launch.
2. Entry by other generic applicants after separate settlements.
3. Invalidation of core patents in parallel litigation.
4. FDA approval of a design-around formulation.
5. Loss of practical exclusivity despite remaining narrow patents.
6. Revenue erosion from an authorized generic.
7. Antitrust scrutiny of settlement or distribution arrangements.
8. Product switching by pharmacies, insurers, and treatment providers.

The later Federal Circuit treatment of the ’514 patent increased the importance of other formulation patents and commercial barriers. Indivior could no longer rely on a single broad patent theory to control all generic film competition.

Key Takeaways

• Indivior sued Alvogen in the District of Delaware over a Paragraph IV ANDA for generic buprenorphine/naloxone sublingual film.
• The principal patents included U.S. Patent Nos. 8,603,514 and 8,900,497.
• The action ended through settlement and stipulated dismissal, not a publicly reported final merits judgment against Alvogen.
• The full settlement terms and precise launch provisions were not disclosed in the public case record.
• The dispute involved small-molecule generic regulation, not biosimilar regulation.
• Indivior’s patent estate had commercial value but faced written-description, enablement, obviousness, and design-around risks.
• Later Federal Circuit decisions weakened the ’514 patent’s broad enforcement position.
• Generic entry risk depended on parallel litigation, Orange Book listings, settlement terms, FDA approval, and the number of approved competitors.

FAQs About Indivior v. Alvogen Pine Brook

Was Alvogen found to infringe Suboxone patents?

No publicly reported final merits judgment in 1:15-cv-00477 established that Alvogen infringed the asserted patents. The case ended through settlement and stipulated dismissal.

Did Alvogen receive permission to launch generic Suboxone Film?

The public docket does not disclose the complete settlement terms or establish the precise launch date. Any launch authorization would have depended on the confidential agreement and FDA approval.

Was U.S. Patent No. 8,603,514 invalidated?

The Federal Circuit later held asserted claims of the ’514 patent invalid for lack of adequate written-description support in separate litigation. That ruling did not arise from a final merits judgment in the Alvogen action.[4]

Did the Alvogen case involve Suboxone tablets?

The litigation concerned generic buprenorphine/naloxone sublingual film, not simply the earlier tablet formulation. Film-specific formulation and delivery claims were central to the dispute.

Could another generic launch after Alvogen settled?

Yes. Other ANDA applicants could pursue separate Paragraph IV litigation, settle independently, obtain approval, or enter after relevant patents and exclusivity periods expired. The Alvogen settlement did not resolve every generic applicant’s rights.

References

1. U.S. District Court for the District of Delaware. (2015). Indivior Inc. v. Alvogen Pine Brook LLC, No. 1:15-cv-00477, docket record.

2. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j)(5)(B)(iii).

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).

4. United States Court of Appeals for the Federal Circuit. (2019). Indivior Inc. v. Dr. Reddy’s Laboratories, S.A., 930 F.3d 1325.